What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026? [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
Viking could be an acquisition target given its cash and drug pipeline. 10 stocks we like better than Viking Therapeutics › Investors in biotechnology company Viking Therapeutics (NASDAQ: VKTX) had a rollercoaster ride in 2025, driven by clinical trial data, or rather, the perception of the clinical trial data. Let's take a brief look at what happened and how the stock is shaping up for 2026. The narrative around the company is dominated by its lead pipeline drug, VK2735. It's a Dual GLP-1 /GIP agonist in development for diabetes and, more importantly from a financial perspective, obesity. It's set to compete with well-known blockbuster weight-loss drugs, Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide). VK2735 is being developed in both subcutaneous (under the skin) and oral forms. The oral version is especially appealing because many patients prefer pills over injections, pills can be stored at room temperature, and they are easier to take. As yo
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- The Commoditization Of GLP-1s: Why Viking's Maintenance Hedge Is Falling Short [Seeking Alpha]Seeking Alpha
- Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026PR Newswire
- 2 Biotech Stocks Set to Rebound in 2026 [Yahoo! Finance]Yahoo! Finance
- Why Viking Therapeutics (VKTX) Is Down 6.5% After Publishing VK2735 Phase 2 Obesity Trial Results And What's Next [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (VKTX) Advances Obesity Drug Development and Expands Metabolic Disease Pipeline [Yahoo! Finance]Yahoo! Finance
VKTX
Earnings
- 10/22/25 - Miss
VKTX
Analyst Actions
- 11/12/25 - Canaccord Genuity
VKTX
Sec Filings
- 1/26/26 - Form 4
- 1/26/26 - Form 3
- 1/5/26 - Form 4
- VKTX's page on the SEC website